Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

The lymphatic vasculature is involved in the pathogenesis of acute cardiac injuries, but little is known about its role in chronic cardiac dysfunction. Here, we demonstrate that angiotensin II infusion induced cardiac inflammation and fibrosis at 1 week and caused cardiac dysfunction and impaired lymphatic transport at 6 weeks in mice, while co-administration of VEGFCc156s improved these parameters. To identify novel mechanisms underlying this protection, RNA sequencing analysis in distinct cell populations revealed that VEGFCc156s specifically modulated angiotensin II-induced inflammatory responses in cardiac and peripheral lymphatic endothelial cells. Furthermore, telemetry studies showed that while angiotensin II increased blood pressure acutely in all animals, VEGFCc156s-treated animals displayed a delayed systemic reduction in blood pressure independent of alterations in angiotensin II-mediated aortic stiffness. Overall, these results demonstrate that VEGFCc156s had a multifaceted therapeutic effect to prevent angiotensin II-induced cardiac dysfunction by improving cardiac lymphatic function, alleviating fibrosis and inflammation, and ameliorating hypertension.

Informations de copyright

© 2020, Song et al.

Déclaration de conflit d'intérêts

LS, XC, TS, BL, JP is an employee at Pfizer inc, TC was an employee at Pfizer inc and is currently an employee at Acceleron Pharma, MN was an employee at Pfizer Inc and is currently an employee at Eisai Inc, SA, KH, AS, HS, SA, YA, SK, AR, CR, FV, MB, FS, RR is an employee at Pfizer Inc, WS consultant for Pfizer.